10-Q: BriaCell Therapeutics Reports Q2 2025 Results, Highlights Clinical Advancements and Financial Activities

BriaCell Therapeutics Corp. announces its financial results for the quarter ended January 31, 2025, alongside updates on its clinical trials and recent financial activities, including multiple offerings and a reverse stock split.

Summary

• BriaCell Therapeutics Corp. reported its financial results for the quarter ended January 31, 2025.
• The company is advancing its Bria-IMT targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer, which has received Fast Track Designation from the U.S. FDA.
• BriaCell is also conducting a Phase 1/2 study to evaluate Bria-OTS, its personalized next-generation immunotherapy, alone and in combination with an immune checkpoint inhibitor.
• A reverse stock split of 1-for-15 was approved on January 3, 2025, and became effective on January 24, 2025.
• The company completed several registered direct offerings, including $8.5 million in September 2024, $5 million in October 2024, and $5.55 million in December 2024.
• In February 2025, BriaCell closed a public offering for $3.05 million.
• The net loss for the three months ended January 31, 2025, was $6,337,828, compared to $11,333,910 for the same period in 2024.
• Research, development, and clinical trial expenses for the three months ended January 31, 2025, were $5,684,777, compared to $8,257,455 for the same period in 2024.
• The company's accumulated deficit as of January 31, 2025, was $97,537,292.
• The company's cash and cash equivalents at the end of the period were $5,013,654.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there are positive signs such as decreased net loss and research expenses compared to the previous year, and successful capital raising activities. However, the going concern uncertainty and accumulated deficit temper the positive aspects.

Positives

• The company's net loss decreased for the three months ended January 31, 2025, compared to the same period in 2024.
• Research, development, and clinical trial expenses decreased for the three months ended January 31, 2025, compared to the same period in 2024.
• BriaCell secured additional funding through multiple offerings, strengthening its financial position.
• The Bria-IMT pivotal Phase 3 study received FDA Fast Track designation, potentially accelerating the review process.
• Cash and cash equivalents increased to $5,013,654 at the end of the period.

Negatives

• The company has an accumulated deficit of $97,537,292 as of January 31, 2025.
• The company continues to devote substantially all of its efforts toward research, development, and clinical activities and has sustained operating losses and expects such losses to continue in the foreseeable future.
• The net loss for the six months ended January 31, 2025, increased compared to 2024.

Risks

• The company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to obtain the necessary financing to meet its obligations.
• The uncertainty of the company's ability to raise such financial capital casts substantial doubt on the company's ability to continue as a going concern.
• The company is exposed to financial risk arising from fluctuations in foreign exchange rates.

Future Outlook

The Company intends to use the net proceeds from recent offerings for working capital requirements, general corporate purposes, and the advancement of business objectives.

Management Comments

• Management believes that it can be successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so.
• There is no assurance that any funds raised will be sufficient to enable the Company to attain profitable operations or continue as a going concern.

Industry Context

The company operates in the clinical-stage biotechnology industry, focusing on developing novel immunotherapies for cancer care, which is a growing area of interest in the fight against cancer.

Comparison to Industry Standards

• The company's Phase 2 clinical study showed a one-year survival rate of 55% for patients treated with the Bria-IMT regimen, which exceeds the survival data of the current standard of care for similar patients.
• The median overall survival of 15.6 months in patients treated with the phase 3 formulation of Bria-IMT since 2022 was reported, which compares favorably with 5.9-9.8 months reported for similar patients in the literature.
• Comparable analysis of 1 year survival for the BriaCell Phase 2 study shows that the Bria-IMT plus CPI has a 55% survival rate compared to Cortes et al. with ~38-40 %, Kazmi et al. with 30-38 %, Bardia et al. (TPC arm) with ~23 %, and Rugo et al (TPC arm) with 47%.

Management Changes

Stakeholder Impact

• Shareholders are impacted by the reverse stock split and the multiple offerings.
• Patients with metastatic breast cancer may benefit from the advancements in Bria-IMT and Bria-OTS therapies.
• Employees are impacted by the company's financial performance and its ability to continue operations.

Next Steps

• The company will continue to advance its Bria-IMT targeted immunotherapy in the pivotal Phase 3 study.
• The company will continue to conduct the Phase 1/2 study to evaluate Bria-OTS.
• The company intends to raise additional capital to achieve its business plan objectives.

Key Dates